Gotowa bibliografia na temat „Digoxin”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Digoxin”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Digoxin"
Wang, Kai-di, Xiang Ding, Nan Jiang, Chao Zeng, Jing Wu, Xian-yi Cai, Aubryanna Hettinghouse i in. "Digoxin targets low density lipoprotein receptor-related protein 4 and protects against osteoarthritis". Annals of the Rheumatic Diseases 81, nr 4 (1.12.2021): 544–55. http://dx.doi.org/10.1136/annrheumdis-2021-221380.
Pełny tekst źródłaWermeling, Daniel P., Carinda J. Feild, Deborah A. Smith, Mary H. H. Chandler, G. Dennis Clifton i Duane A. Boyle. "Effects of Long‐Term Oral Carvedilol on the Steady‐State Pharmacokinetics of Oral Digoxin in Patients With Mild to Moderate Hypertension". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 14, nr 5 (10.09.1994): 600–606. http://dx.doi.org/10.1002/j.1875-9114.1994.tb02857.x.
Pełny tekst źródłaScalese, Michael J., i Dominick J. Salvatore. "Role of Digoxin in Atrial Fibrillation". Journal of Pharmacy Practice 30, nr 4 (10.04.2016): 434–40. http://dx.doi.org/10.1177/0897190016642361.
Pełny tekst źródłaQadhi, Rawabi, Tran Tran, Stefanie Lip, Ogor Team, Linsay Macallum i Sandosh Padmanabhan. "ASSESSING THE CLINICAL IMPACT OF PROTON PUMP INHIBITOR-DIGOXIN INTERACTIONS: A RETROSPECTIVE COHORT STUDY OF HOSPITALIZATION AND MORTALITY RISK". Journal of Hypertension 42, Suppl 1 (maj 2024): e253-e254. http://dx.doi.org/10.1097/01.hjh.0001022092.07013.e9.
Pełny tekst źródłaRen, Yulin, Sijin Wu, Joanna E. Burdette, Xiaolin Cheng i A. Douglas Kinghorn. "Structural Insights into the Interactions of Digoxin and Na+/K+-ATPase and Other Targets for the Inhibition of Cancer Cell Proliferation". Molecules 26, nr 12 (16.06.2021): 3672. http://dx.doi.org/10.3390/molecules26123672.
Pełny tekst źródłaSuryoputri, Masita Wulandari, Laksmi Maharani i Ika Mustikaningtias. "Penyesuaian Dosis Digoxin pada Pasien Gagal Jantung di RSUD Margono Soekardjo Purwokerto". JURNAL ILMU KEFARMASIAN INDONESIA 19, nr 2 (28.12.2021): 248. http://dx.doi.org/10.35814/jifi.v19i2.778.
Pełny tekst źródłaCremer, Edivaldo, Almir Conrrado Rodrigues de Lima, Larissa Laila Cassarotti, Gabrielle Rodrigues Munhoz, Romulo Jordão Barbosa Pedrinho i Roberto Kenji Nakamura Cuman. "Mortalidade de indivíduos idosos cardíacos tratados com digoxina". Revista Recien - Revista Científica de Enfermagem 10, nr 29 (31.03.2020): 120–28. http://dx.doi.org/10.24276/rrecien2358-3088.2020.10.29.120-128.
Pełny tekst źródłaAllen, Nancy M., Gary D. Dunham, Jeffrey M. Sailstad i John W. A. Findlay. "Clinical and Pharmacokinetic Profiles of Digoxin Immune Fab in Four Patients with Renal Impairment". DICP 25, nr 12 (grudzień 1991): 1315–20. http://dx.doi.org/10.1177/106002809102501205.
Pełny tekst źródłaMoffett, Brady S., April Garner, Troy Zapata, Jeffrey Orcutt, Mary Niu i Keila N. Lopez. "Serum digoxin concentrations and clinical signs and symptoms of digoxin toxicity in the paediatric population". Cardiology in the Young 26, nr 3 (27.04.2015): 493–98. http://dx.doi.org/10.1017/s1047951115000505.
Pełny tekst źródłaDasgupta, Amitava, Laura Kidd, Brian J. Poindexter i Roger J. Bick. "Interference of Hawthorn on Serum Digoxin Measurements by Immunoassays and Pharmacodynamic Interaction With Digoxin". Archives of Pathology & Laboratory Medicine 134, nr 8 (1.08.2010): 1188–92. http://dx.doi.org/10.5858/2009-0404-oa.1.
Pełny tekst źródłaRozprawy doktorskie na temat "Digoxin"
Alexandrovich, Susan K. "Characterization of monoclonal antibodies against digoxin /". Online version of thesis, 1987. http://hdl.handle.net/1850/10681.
Pełny tekst źródłaMatthewson, Beryl Ellen. "Digoxin-like immunoreactive substances in the neonate". Thesis, University of British Columbia, 1988. http://hdl.handle.net/2429/28022.
Pełny tekst źródłaMedicine, Faculty of
Pathology and Laboratory Medicine, Department of
Graduate
Hui, James. "Analysis for digoxin and metabolites in serum and digoxin disposition in the elderly with gastrointestinal disease after two oral dosage forms /". The Ohio State University, 1988. http://rave.ohiolink.edu/etdc/view?acc_num=osu1487587604130428.
Pełny tekst źródłaHallberg, Pär. "Pharmacogenomics of antihypertensive treatment & clinical pharmacological studies of digoxin treatment /". Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5782.
Pełny tekst źródłaCavet, Megan Elizabeth. "Intestinal secretion of organic solutes". Thesis, University of Newcastle Upon Tyne, 1996. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.318538.
Pełny tekst źródłaSvensson, Åsa. "Applications of a new logic to old drugs: angiogenesis inhibition in neuroblastoma /". Uppsala : Acta Universitatis Upsaliensis : Univ.-bibl. [distributör], 2003. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3458.
Pełny tekst źródłaBARROS, Isabel Cristina Medeiros. "Monitoração terapêutica das concentrações plásmaticas da digoxina em pacientes com insuficiência cardíaca". Universidade Federal de Goiás, 2008. http://repositorio.bc.ufg.br/tede/handle/tde/1703.
Pełny tekst źródłaIt was investigated the clinical, lab and plasma digoxin concentration profiles in 15 cardiac heart failure (CHF) outpatients of the Cardiac Heart Service of the Goias Federal University Clinical Hospital. It was aimed to know plasma digoxin concentration profile in 15 cardiac heart failure (CHF) outpatients by two analytical methods, taking account clinical, laboratorial, habits, anthropometric data and drug usage. Digoxin dosage was developed by LC/MS/MS and immunoassay methods; questionnaire and consults handbooks were performed. Results and Conclusions: 87% of the patients who over 46 years of age (33% above 61), the masculine majority; the IC of Chagas disease origin presented greater occurrence, followed of the hipertensive and idiopatic (59%); IC functional classroom II (53.33%); hypertension and diabetes had been distinguished as co-morbidities (26.67% and 20%); tobaccoism, overweight and obesity degree I had presented low occurrence. No patients presented relevant clinical data suggestive of digitalis intoxication. No observed changes in biochemical and hematological exams. The ejection fractions were good by means 41.7 ± 9%. Some drugs with interaction potential had been associated to the treatment, apparently without alterations. Statistical significative difference between both methods was observed (P < 0.05, ANOVA, Tukey Test). In the immunoassay method, all the patients were inside of the therapeutical range (0, 5-2, 0 ng/mL), whereas for the LC-MS/MS method, 8 patients they would be in subtherapeutical concentrations. However, no patient presented signals or symptoms of poisoning or inefficacy of the digoxin, demonstrating biological variability. The two methods are useful, since that it has a correlation with the clinical and laboratorial state of the patients.
Investigou-se o perfil clínico, laboratorial e as concentrações de digoxina plasmática em 15 pacientes com insuficiência cardíaca (IC) atendidos no Ambulatório de Insuficiência Cardíaca do HC-UFG. Objetivou-se estudar o perfil de concentrações plasmáticas de digoxina em pacientes com IC, utilizando dois métodos analíticos, e descrever a digoxinemia considerando os dados clínicos, laboratoriais, hábitos, IMC e consumo de medicamentos. A metodologia utilizada consistiu de cromatografia líquida de alta eficiência acoplada a espectrometria de massas (LC/MS/MS) e Imunoensaio, aplicação de questionário e consulta a prontuários. Como resultados, observou-se: 87% dos pacientes maiores que 46 anos de idade (33% acima de 61), a maioria masculina, a IC de origem chagásica apresentou maior ocorrência, seguida da hipertensiva e idiopática (59%); IC classe funcional II (53,33%); hipertensão e diabetes destacaram-se como co-morbidades (26,67% e 20%); tabagismo, sobrepeso e obesidade grau I apresentaram baixa ocorrência. Nenhum dos pacientes apresentou dados clínicos relevantes sugestivos de intoxicação digitálica. Não houve alterações em exames bioquímicos e hematológicos. A fração de ejeção média foi 41,7 ± 9%, portanto nenhum paciente apresentou FE como preditor de mau prognóstico. Vários fármacos com potencial de interação estiveram associados ao tratamento, aparentemente sem alterações. Houve diferença significativa (P < 0,05, ANOVA, Teste de Tukey) entre os métodos analíticos. No método de imunoensaio, todos os pacientes estavam dentro da faixa terapêutica (0,5-2,0 ng/mL), enquanto que pelo método LC-MS/MS, 8 pacientes estariam em sub-dosagens. Entretanto, nenhum paciente apresentou sinais ou sintomas de intoxicação ou de ineficácia da digoxina, demonstrando variabilidade biológica. Os dois métodos são úteis, desde que haja uma correlação com o estado clínico e laboratorial dos pacientes.
Embree, Leanne. "Development of a sensitive, quantitative high-performance liquid chromatographic assay for the measurement of digoxin in patient groups with high levels of digoxin-like immunoreactive substances". Thesis, University of British Columbia, 1989. http://hdl.handle.net/2429/29093.
Pełny tekst źródłaPharmaceutical Sciences, Faculty of
Graduate
Hallberg, Pär. "Pharmacogenomics of Antihypertensive Treatment & Clinical Pharmacological Studies of Digoxin Treatment". Doctoral thesis, Uppsala universitet, Institutionen för medicinska vetenskaper, 2005. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5782.
Pełny tekst źródłaVetticaden, Santosh John. "Evaluation of Analytical, Pharmacokinetic and Pharmacodynamic Methods for the Study of Digoxin". VCU Scholars Compass, 1985. http://scholarscompass.vcu.edu/etd/5103.
Pełny tekst źródłaKsiążki na temat "Digoxin"
Buchko, Sandra. The effect of nebulized salbutamol on serum digoxin concentration. [Ottawa: Ottawa General Hospital, 1991.
Znajdź pełny tekst źródłauniversitet, Odense, red. Digoxin interactions: The influence of quinidine and verapamil on the pharmacokinetics and receptor binding of digitalis glycosides. Stockholm: distributed by the Almqvist & Wiksell Periodical Company, 1985.
Znajdź pełny tekst źródłaKlüppel, Arnulf. Untersuchungen zur dosisunabhängigen Pharmakokinetik von Digoxin. [s.l.]: [s.n.], 1986.
Znajdź pełny tekst źródłaBissland, Ted. Death shift: The digoxin murders at "Sick Kids". Toronto: Bantam, 1985.
Znajdź pełny tekst źródłaKurup, Ravikumar, i Parameswaran Achutha Kurup. The third element: Actinidic archaea, digoxin, and the biological universe. Hauppauge, N.Y: Nova Science Publishers, 2011.
Znajdź pełny tekst źródłaKurup, Ravikumar. Hypothalamic digoxin, cerebral dominance and brain function in health and diseases. New York: Nova Science Publishers, Inc., 2003.
Znajdź pełny tekst źródłaJoreteg, Torbjörn. Digoxin binding to skeletal muscle: Factors of importance for an activity dependency. [s.l.]: [s.n.], 1985.
Znajdź pełny tekst źródłaStenzel, Joachim. Der Einfluss von Nisoldipin auf die Digoxin- und Digitoxinplasmaspiegel und hämodynamische Effekte. [s.l.]: [s.n.], 1987.
Znajdź pełny tekst źródłaDüsseldorf, Universität, red. Der Einfluss von Digoxin auf die Kernreihenbildung in den Herzmuskelzellen des Schweines. [s.l.]: [s.n.], 1987.
Znajdź pełny tekst źródłaPeter, Inge. Dosis-Wirkungsbeziehungen extrakardialer Effekte von Digoxin und Meproscillarin an gesunden Versuchspersonen: (placebokontrollierte Doppelblindstudie). [s.l.]: [s.n.], 1985.
Znajdź pełny tekst źródłaCzęści książek na temat "Digoxin"
Gebran, Nicole. "Digoxin". W Textbook of Clinical Pediatrics, 2605–8. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-02202-9_275.
Pełny tekst źródłaBeyer, Karl-Heinz. "Digoxin". W Biotransformation der Arzneimittel, 202–4. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74386-3_107.
Pełny tekst źródłaVidal, C., i W. R. Külpmann. "Digoxin". W Springer Reference Medizin, 702–3. Berlin, Heidelberg: Springer Berlin Heidelberg, 2019. http://dx.doi.org/10.1007/978-3-662-48986-4_892.
Pełny tekst źródłaVidal, C., i W. R. Külpmann. "Digoxin". W Lexikon der Medizinischen Laboratoriumsdiagnostik, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2018. http://dx.doi.org/10.1007/978-3-662-49054-9_892-1.
Pełny tekst źródłaDasgupta, Amitava. "Digoxin". W Handbook of Drug Monitoring Methods, 111–31. Totowa, NJ: Humana Press, 2008. http://dx.doi.org/10.1007/978-1-59745-031-7_6.
Pełny tekst źródłaWilson, John Fawcett. "Digoxin". W The Immunoassay Kit Directory, 1515–32. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0679-5_15.
Pełny tekst źródłaPeter, Helga, i Thomas Penzel. "Digoxin". W Springer Reference Medizin, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-54672-3_451-1.
Pełny tekst źródłaChen, Ying, Lan Sun i Guan-Hua Du. "Digoxin". W Natural Small Molecule Drugs from Plants, 49–58. Singapore: Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-10-8022-7_8.
Pełny tekst źródłaSchneider, Achim, Günther Schlunck i Viola Sieber. "Digoxin". W Geburtshilfefibel, 257–59. Berlin, Heidelberg: Springer Berlin Heidelberg, 1991. http://dx.doi.org/10.1007/978-3-642-97317-8_54.
Pełny tekst źródłaAhmed, Hesham M., Christopher T. Aquina, Vicente H. Gracias, J. Javier Provencio, Mariano Alberto Pennisi, Giuseppe Bello, Massimo Antonelli i in. "Digoxin Toxicity". W Encyclopedia of Intensive Care Medicine, 722. Berlin, Heidelberg: Springer Berlin Heidelberg, 2012. http://dx.doi.org/10.1007/978-3-642-00418-6_1486.
Pełny tekst źródłaStreszczenia konferencji na temat "Digoxin"
Karthikeyan, Ganesan. "28 Should we be using digoxin in 2018?" W 2nd Asia Pacific Advanced Heart Failure Forum (APAHFF 2018), 16th November 2018, Hong Kong. BMJ Publishing Group Ltd, British Cardiovascular Society and Asia Pacific Heart Association, 2019. http://dx.doi.org/10.1136/heartasia-2019-apahff.28.
Pełny tekst źródłaPowell, C., M. Barrett, K. Flynn, D. Meenaghan i K. McDonald. "54 A year in the life of digoxin". W Irish Cardiac Society 74th Annual Scientific Meeting & AGM, October 12th–14th 2023, Killashee House Hotel, Kildare, Ireland. BMJ Publishing Group Ltd and British Cardiovascular Society, 2023. http://dx.doi.org/10.1136/heartjnl-2023-ics.54.
Pełny tekst źródłaGranell, C. Liñana, L. Belles Medall, O. Pascual Marmaneu, R. Ferrando Piqueres, M. Medoza Aguilera, T. Alvarez Martin i T. Garcia Martinez. "PKP-008 Implementation of a monitoring protocol for digoxin". W 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.436.
Pełny tekst źródłaMartínez Simón, JJ, A. Martín Suárez, AM Gómez Pedrero i M. Pérez Encinas. "5PSQ-023 Adequate digoxin dosage in patients with digitalis toxicity". W 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.456.
Pełny tekst źródłaRodríguez Esquíroz, A., C. Leralta González, M. Jiménez Meseguer, ÁL Salcedo Mingorranz, B. García Díaz, M. Sarobe Carricas i MF Hurtado Gómez. "5PSQ-010 Digoxin adjustment: comparative analysis of three pharmacokinetic software". W 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.237.
Pełny tekst źródłaSchwegman, A., S. Herasevich, Y. Subat, O. Gajic i C. Bennett. "Digoxin Use in Patients with Sepsis: A Single-Center Retrospective Cohort Study". W American Thoracic Society 2019 International Conference, May 17-22, 2019 - Dallas, TX. American Thoracic Society, 2019. http://dx.doi.org/10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a6500.
Pełny tekst źródłaMagro Vázquez, C., C. González Trigueros, AL Salcedo Mingoarranz, MM Noceda Urarte, M. Herrero Fernández, MT Sarobe Carricas, G. Baldominos Utrilla i B. García Díaz. "4CPS-103 Pharmacokinetic interaction study of osimertinib and digoxin: a case report". W 27th EAHP Congress, Lisbon, Portugal, 22-23-24 March 2023. British Medical Journal Publishing Group, 2023. http://dx.doi.org/10.1136/ejhpharm-2023-eahp.119.
Pełny tekst źródłaAbbasi, A., A. Nikfarjam i J. Mohammadnejad. "Simulation of digoxin single molecule detection through resonant frequency shift of a CNT". W 2013 First RSI/ISM International Conference on Robotics and Mechatronics (ICRoM 2013). IEEE, 2013. http://dx.doi.org/10.1109/icrom.2013.6510132.
Pełny tekst źródłaLópez-Sepúlveda, R., E. Espínola García, MS Martín Sances, S. Anaya Ordóñez, MA García Lirola i J. Cabeza Barrera. "PKP-006 Pharmacist’s role in clinical pharmacokinetic monitoring of digoxin: minimising toxic effects". W 22nd EAHP Congress 22–24 March 2017 Cannes, France. British Medical Journal Publishing Group, 2017. http://dx.doi.org/10.1136/ejhpharm-2017-000640.434.
Pełny tekst źródłaPothal, S., N. Tengli, N. Patel i A. Behera. "Efficacy of Digoxin in isolated Right ventricular Dysfunction due to Chronic Pulmonary Diseases". W ERS International Congress 2022 abstracts. European Respiratory Society, 2022. http://dx.doi.org/10.1183/13993003.congress-2022.135.
Pełny tekst źródła